Response to: Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer et al

Manuel Francisco Ugarte-Gil
,
Maximilian F. Konig
,
Peter Korsten
,
Francis Berenbaum
,
Alfred Hyoungju Kim(corresponding author)
,
Jeffrey A. Sparks

*Corresponding author for this work

Medicina humana
,
Universidad Científica del Sur
,
Johns Hopkins University
,
University Medical Center Göttingen
,
Sorbonne Université
,
Washington University in Saint Louis

Research Output:

Contribution to journal

Letter

Peer-review

Open access

Publication Information

Output type

Research Output:

Contribution to journal

Letter

Peer-review

Original language

English

Article number

e162

Journal (Volume, Issue Number)

Annals of the Rheumatic Diseases (Volume 81, Issue 9)

Publication milestones

Accepted/In press - 2020
Published - 01/09/2022

Publication status

Published - 01/09/2022

ISSN

0003-4967

Publication IDs

Scopus: 85092521656
PubMed: 32759257

Funding Details

Competing interests PK reports personal fees from GlaxoSmithKline, Sanofi-Aventis, Pfizer, Abbvie, Novartis Pharma, Eli Lilly and Bristol-Myers Squibb. FB reports personal fees from Boehringer, Bone Therapeutics, Expanscience, Galapagos, Gilead, GSK, Merck Sereno, MSD, Nordic, Novartis, Pfizer, Regulaxis, Roche, Sandoz, Sanofi, Servier, UCB, Peptinov, TRB Chemedica and 4P Pharma. AHK reports grants from National Institutes of Health (NIH)/National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and Rheumatology Research Foundation and personal fees from Exagen Diagnostics, Inc. and GlaxoSmithKline. Drs Liew and Graef have disclosed no conflicts of interest or competing interests. JAS reports grants from NIH/ NIAMS/National Institute of Allergy and Infectious Diseases/Autoimmune Centers of Excellence, the Rheumatology Research Foundation, the Brigham Research Institute, and the R. Bruce and Joan M. Mickey Research Scholar Fund as well as personal fees from Bristol-Myers Squibb, Gilead, Inova, Janssen and Optum.

FundersFunding numbers

Autoimmune Centers of Excellence

NIH

NIAID

NIAMS

T32AR048522

GSK

Gilead Sciences

RRF

BRI